ecteinascidin 743 has been researched along with Bone Cancer in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 13 (72.22) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Chiba, K; Horiuchi, K; Inoue, M; Ishizaka, T; Matsuhashi, Y; Rikitake, H; Susa, M; Taguchi, E | 1 |
| Bongiovanni, L; Botti, L; Burocchi, A; Cancila, V; Cappetti, B; Chiodoni, C; Colombo, MP; Galvan, S; Garofalo, C; Manara, MC; Parenza, M; Ratti, C; Sangaletti, S; Scotlandi, K; Torselli, I; Tripodo, C; Valenti, CF | 1 |
| Aglietta, M; Aliberti, S; Bardelli, A; Bartolini, A; Bertulli, R; Boccone, P; Chiabotto, G; D'Ambrosio, L; D'Incalci, M; Dei Tos, AP; Ferrari, S; Grignani, G; Marchesi, E; Miano, S; Novara, L; Palmerini, E; Piana, R; Picci, P; Pignochino, Y; Pisacane, A; Sangiolo, D; Stacchiotti, S; Tolomeo, F; Zucchetti, M | 1 |
| Daignault, S; Hofbauer, LC; Jones, JD; Koh, AJ; McCauley, LK; Paige, D; Roca, H; Shiozawa, Y; Sinder, BP; Soki, FN; Thiele, S | 1 |
| Hayashi, K; Igarashi, K; Miwa, S; Takeuchi, A; Tsuchiya, H; Yamamoto, N | 1 |
| Bouvet, M; Chawla, SP; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N | 1 |
| Gastaud, L; Ianessi, A; Italiano, A; Le Morvan, V; Pourquier, P; Saâda-Bouzid, E; Thariat, J; Thyss, A | 1 |
| Araki, N; Hiraga, H; Hiruma, T; Horiuchi, K; Kawai, A; Kikuta, K; Kunisada, T; Matsumine, A; Morioka, H; Nakayama, R; Nishimoto, K; Sugiura, H; Susa, M; Takahashi, M; Takahashi, S; Ueda, T; Yonemoto, T | 1 |
| Baresic, T; Buonadonna, A; Canzonieri, V; Corona, G; Lara, DP; Miolo, G; Santeufemia, DA; Viel, A | 1 |
| Antony, S; Guirouilh-Barbat, J; Pommier, Y | 1 |
| Budd, GT; Wesolowski, R | 1 |
| Chen, QR; Griffin, LB; Grohar, PJ; Helman, LJ; Khan, J; Khanna, C; Pommier, Y; Yeung, C | 1 |
| Douer, D; Liu, SV; Tahbaz, A; Zneimer, S | 1 |
| Adamson, PC; Baker, KS; Baruchel, S; Blaney, SM; Krailo, M; Lee-Scott, M; Pappo, A; Villaluna, D; Wu, B | 1 |
| Grohar, PJ; Helman, LJ | 1 |
| Benini, S; Cerisano, V; D'Incalci, M; Faircloth, G; Manara, MC; Mercuri, M; Perdichizzi, S; Picci, P; Reverter-Branchat, G; Scotlandi, K; Serra, M; Strammiello, R | 1 |
| Bagatell, R; Demetri, GD; Goorin, AM; Gorlick, R; Guzman, C; Harmon, D; Healey, JH; Huvos, AG; Jimeno, J; Kolb, EA; Laverdiere, C; Maki, RG; Meyers, PA; Ruiz-Casado, A; Supko, JG; Wexler, L | 1 |
| Brain, E; Cottu, P; Cvitkovic, E; Delaloge, S; Goldwasser, F; Jimeno, J; Marty, M; Misset, JL; Raymond, E; Riofrio, M; Taamma, A; Yovine, A | 1 |
3 review(s) available for ecteinascidin 743 and Bone Cancer
| Article | Year |
|---|---|
Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Drug Therapy; Furans; Humans; Immunotherapy, Adoptive; Indazoles; Ipilimumab; Ketones; Nivolumab; Osteosarcoma; Progression-Free Survival; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Trabectedin | 2019 |
Use of chemotherapy for patients with bone and soft-tissue sarcomas.
Topics: Antineoplastic Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Dioxoles; Humans; Muscle Neoplasms; Osteosarcoma; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2010 |
Prospects and challenges for the development of new therapies for Ewing sarcoma.
Topics: Antineoplastic Agents; Bone Neoplasms; Camptothecin; Clinical Trials as Topic; Dioxoles; Epigenesis, Genetic; Humans; Molecular Targeted Therapy; Poly(ADP-ribose) Polymerase Inhibitors; Sarcoma, Ewing; Somatomedins; Tetrahydroisoquinolines; Trabectedin | 2013 |
5 trial(s) available for ecteinascidin 743 and Bone Cancer
| Article | Year |
|---|---|
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Female; Humans; Italy; Male; Middle Aged; Osteosarcoma; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Sarcoma; Soft Tissue Neoplasms; Time Factors; Trabectedin | 2018 |
Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chondrosarcoma; Chondrosarcoma, Mesenchymal; Dioxoles; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Connective and Soft Tissue; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2016 |
A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Algorithms; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Child, Preschool; Dioxoles; Dose-Response Relationship, Drug; Female; Humans; Male; Medical Oncology; Pediatrics; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Societies, Medical; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2012 |
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Dioxoles; Female; Humans; Isoquinolines; Male; Middle Aged; Osteosarcoma; Salvage Therapy; Tetrahydroisoquinolines; Trabectedin | 2003 |
Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Dioxoles; Disease Progression; Female; Humans; Isoquinolines; Liver; Male; Middle Aged; Neutropenia; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2001 |
10 other study(ies) available for ecteinascidin 743 and Bone Cancer
| Article | Year |
|---|---|
Trabectedin suppresses osteosarcoma pulmonary metastasis in a mouse tumor xenograft model.
Topics: Adolescent; Animals; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Heterografts; Humans; Lung Neoplasms; Mice; Neoplasm Metastasis; Osteosarcoma; Trabectedin | 2022 |
Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors.
Topics: Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Cellular Reprogramming; Core Binding Factor Alpha 1 Subunit; Dioxoles; Humans; Immunotherapy; Lung Neoplasms; Osteosarcoma; Programmed Cell Death 1 Receptor; T-Lymphocytes; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment; Tumor Suppressor Protein p53 | 2017 |
Trabectedin Reduces Skeletal Prostate Cancer Tumor Size in Association with Effects on M2 Macrophages and Efferocytosis.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Bone Marrow; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytokines; Disease Models, Animal; Humans; Immunohistochemistry; Macrophage Activation; Macrophages; Male; Mice; Phagocytosis; Phenotype; Prostatic Neoplasms; Trabectedin; Xenograft Model Antitumor Assays | 2019 |
Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model.
Topics: Adolescent; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Humans; Irinotecan; Male; Mice, Nude; Osteosarcoma; Topoisomerase I Inhibitors; Trabectedin | 2019 |
Major efficacy of trabectedin in 2 metastatic osteosarcoma patients with wild-type Asp1104 ERCC5 tumor status.
Topics: Adolescent; Biomarkers, Tumor; Bone Neoplasms; Dioxoles; DNA-Binding Proteins; Endonucleases; Female; Genetic Markers; Humans; Male; Nuclear Proteins; Osteosarcoma; Polymorphism, Single Nucleotide; Tetrahydroisoquinolines; Trabectedin; Transcription Factors; Treatment Outcome; Young Adult | 2013 |
Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bone Neoplasms; BRCA2 Protein; Dioxoles; Endometrial Neoplasms; Epirubicin; Female; Genes, BRCA2; Germ-Line Mutation; Humans; Ifosfamide; Liver Neoplasms; Middle Aged; Mutation, Missense; Sarcoma, Endometrial Stromal; Tetrahydroisoquinolines; Trabectedin | 2016 |
Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Dioxoles; DNA Damage; DNA Footprinting; DNA Repair; DNA Replication; Histones; Humans; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin; Transcription, Genetic; Tumor Cells, Cultured | 2009 |
Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Cell Line, Tumor; Child; DAX-1 Orphan Nuclear Receptor; Dioxoles; Europe; Gene Expression Regulation, Neoplastic; Humans; Oncogene Proteins, Fusion; Promoter Regions, Genetic; Proto-Oncogene Protein c-fli-1; RNA-Binding Protein EWS; RNA-Binding Protein FUS; Sarcoma; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin; Transcription Factor CHOP | 2011 |
Therapy-related acute myeloid leukemia following treatment with trabectedin for Ewing's sarcoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Dioxoles; Etoposide; Fatal Outcome; Female; Gene Deletion; Gene Rearrangement; Humans; Leukemia, Myeloid, Acute; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Second Primary; Sarcoma, Ewing; Tetrahydroisoquinolines; Topoisomerase Inhibitors; Trabectedin; Young Adult | 2011 |
Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Neoplasms; Cell Differentiation; Dioxoles; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Isoquinolines; Nuclear Proteins; Osteosarcoma; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Retinoblastoma Protein; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |